BUPIVACAINE HYDROCHLORIDE

Post-LOE

bupivacaine hydrochloride

Aspiro Therapeutics

ANDAINJECTIONINJECTABLE

Approved

Mar 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUPIVACAINE HYDROCHLORIDE (bupivacaine hydrochloride) by Aspiro Therapeutics is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 2024.

Drug data last refreshed 21h ago

Mechanism of Action

impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…

Indications (7)

regional anesthesia analgesia for surgery

Worked on BUPIVACAINE HYDROCHLORIDE at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.